This can make you feel less hungry and help you eat less throughout the day, leading to weight loss
[3] Other common adverse effects reported during the clinical trials include back pain, upper respiratory tract infections, melanocyte naevus, decreased appetite, migraine, dizziness, weakness, fatigue, lethargy, sleepiness, hot flashes, abdominal pain, diarrhea, vomiting, flushing, development of warts, spots, and freckles, and itchy skin (between 1% and 10% of people)
It is a small-molecule pan-PPAR agonist developed by the French biotech Inventiva, currently in Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH)
NAD+ AT HOME also aims to support your natural defences whilst optimising performance
Structural and morphological transition in polymer composites for drug delivery